IP Library Granted Patent US 9,138,438
Granted Patent B2
US 9,138,438 · App. 13/199,598 · Granted Sep 22, 2015

Method for protecting a retinal neuronal cell

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,138,438
App. No.
13/199,598
Granted
Sep 22, 2015
Kind
B2
Abstract

A method of protecting a retinal neuronal cell by administering an effective amount of a prostaglandin F2α derivative to a patient. A method of preventing or treating an eye disease associated with retinal neuronal cell damage by administering a therapeutically effective amount of a prostaglandin F2α derivative to a patient.

Claims (12)

1. A method for treating an eye disease selected from the group consisting of abnormal visual field, retinal vascular occlusion, diabetic retinopathy, ischemic optic neuropathy, macular degeneration, retinitis pigmentosa and Leber's disease, the method comprising administering to a patient in need thereof, wherein the patient does not have glaucoma, a therapeutically effective amount of a 15,15-difluoroprostaglandin F2α derivative is a compound represented by the following formula (1) or a salt thereof:

wherein R represents a hydroxyalkyl group, a formyl group, a carboxy group, an isopropoxycarbonyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group or an arylaminocarbonyl group, and when R is an aryloxycarbonyl group or an arylaminocarbonyl group, the aryl moiety thereof may have a substituent.

2. The method according to claim 1 , wherein in the formula (1), R represents a carboxy group or a salt group thereof or an alkoxycarbonyl group.

3. The method according to claim 1 , wherein in the formula (I), R represents a carboxy group or a salt thereof or an isopropoxycarbonyl group.

4. The method according to claim 1 , wherein the compound is 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranor-prostaglandin F2α.

5. The method according to claim 1 , wherein the disease is abnormal visual field.

6. The method according to claim 1 , wherein the disease is retinal vascular occlusion.

7. The method according to claim 1 , wherein the disease is diabetic retinopathy.

8. The method according to claim 1 , wherein the disease is ischemic optic neuropathy.

9. The method according to claim 1 , wherein the disease is macular degeneration.

10. The method according to claim 1 , wherein the disease is retinitis pigmentosa.

11. The method according to claim 1 , wherein the disease is Leber's disease.

Assignments (3)
CHANGE OF NAME Recorded Aug 7, 2018
From: ASAHI GLASS COMPANY, LIMITED
To: AGC INC.
Reel/Frame 046730/0786 →
CORPORATE ADDRESS CHANGE Recorded Nov 9, 2011
From: ASAHI GLASS COMPANY, LIMITED
To: ASAHI GLASS COMPANY, LIMITED
Reel/Frame 027197/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2011
From: ISHIDA, NARUHIRO; SHIMZAKI, ATSUSHI
To: ASAHI GLASS COMPANY, LIMITED; SANTEN PHARMACEUTICAL CO., LTD.
Reel/Frame 027053/0258 →